-
1
-
-
16244371591
-
-
IARC Press: Lyon.
-
Travis WB, Brambilla A, Müller-Hermelinck HK, et al., World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon, 2004.
-
(2004)
World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart
-
-
Travis, W.B.1
Brambilla, A.2
Müller-Hermelinck, H.K.3
-
2
-
-
79251490374
-
New driver mutations in non-small-cell lung cancer
-
Pao W, Girard N,. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-180.
-
(2011)
Lancet Oncol
, vol.12
, pp. 175-180
-
-
Pao, W.1
Girard, N.2
-
3
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
-
Schiller J, Harrington D, Belani C, et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
-
(2002)
N Engl J Med
, vol.346
, pp. 92-98
-
-
Schiller, J.1
Harrington, D.2
Belani, C.3
-
5
-
-
0003964363
-
-
American Cancer Society Atlanta: American Cancer Society Accessed 22 August 2013
-
American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012 [Accessed 22 August 2013]. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-033423.pdf.
-
(2012)
Cancer Facts & Figures 2012
-
-
-
6
-
-
84880917028
-
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
-
Lindeman NI, Cagle PT, Beasley MB, et al., Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8: 823-859.
-
(2013)
J Thorac Oncol
, vol.8
, pp. 823-859
-
-
Lindeman, N.I.1
Cagle, P.T.2
Beasley, M.B.3
-
7
-
-
79551563284
-
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma
-
Travis WD, Brambilla E, Noguchi M, et al., International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 244-285
-
-
Travis, W.D.1
Brambilla, E.2
Noguchi, M.3
-
8
-
-
79960889662
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
-
Zhou C, Wu YL, Chen G, et al., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
-
(2011)
Lancet Oncol
, vol.12
, pp. 735-742
-
-
Zhou, C.1
Wu, Y.L.2
Chen, G.3
-
9
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
10
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
-
11
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak EL, Bang YJ, Camidge DR, et al., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
-
(2010)
N Engl J Med
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
-
12
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
-
Rosell R, Carcereny E, Gervais R, et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
13
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
Shaw TA, Kim D-W, Nakagawa K, et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
-
(2013)
N Engl J Med
, vol.368
, pp. 2385-2394
-
-
Shaw, T.A.1
Kim, D.-W.2
Nakagawa, K.3
-
14
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
-
15
-
-
84875947292
-
New targetable oncogenes in non-small-cell lung cancer
-
Oxnard GR, Binder A, Jänne PA,. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013; 31: 1097-1104.
-
(2013)
J Clin Oncol
, vol.31
, pp. 1097-1104
-
-
Oxnard, G.R.1
Binder, A.2
Jänne, P.A.3
-
16
-
-
20044364940
-
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
-
Shigematsu H, Lin L, Takahashi T, et al., Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 339-346
-
-
Shigematsu, H.1
Lin, L.2
Takahashi, T.3
-
17
-
-
84875937242
-
Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies
-
Li T, Kung H-J, Mack PC, et al., Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31: 1039-1049.
-
(2013)
J Clin Oncol
, vol.31
, pp. 1039-1049
-
-
Li, T.1
Kung, H.-J.2
MacK, P.C.3
-
18
-
-
65949086609
-
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR
-
Sos ML, Koker M, Weir BA, et al., PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009; 69: 3256-3261.
-
(2009)
Cancer Res
, vol.69
, pp. 3256-3261
-
-
Sos, M.L.1
Koker, M.2
Weir, B.A.3
-
19
-
-
37549061078
-
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
-
Engelman JA, Zejnullahu K, Gale CM, et al., PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67: 11924-11932.
-
(2007)
Cancer Res
, vol.67
, pp. 11924-11932
-
-
Engelman, J.A.1
Zejnullahu, K.2
Gale, C.M.3
-
20
-
-
51049123872
-
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
-
Gonzales AJ, Hook KE, Althaus IW, et al., Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008; 7: 1880-1889.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 1880-1889
-
-
Gonzales, A.J.1
Hook, K.E.2
Althaus, I.W.3
-
21
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
Kobayashi S, Boggon TJ, Dayaram T, et al., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
-
(2005)
N Engl J Med
, vol.352
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
-
22
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
Pao W, Miller VA, Politi KA, et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
-
23
-
-
84866255620
-
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
-
Ramalingam SS, Blackhall F, Krzakowski M, et al., Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012; 30: 3337-3344.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3337-3344
-
-
Ramalingam, S.S.1
Blackhall, F.2
Krzakowski, M.3
-
24
-
-
84872693463
-
Dacomitinib, a new therapy for the treatment of non-small cell lung cancer
-
Brzezniak C, Carter CA, Giaccone G,. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2013; 14: 247-253.
-
(2013)
Expert Opin Pharmacother
, vol.14
, pp. 247-253
-
-
Brzezniak, C.1
Carter, C.A.2
Giaccone, G.3
-
25
-
-
34547638047
-
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
-
Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
-
(2007)
Nature
, vol.448
, pp. 561-566
-
-
Soda, M.1
Choi, Y.L.2
Enomoto, M.3
-
26
-
-
84886290631
-
The impact of genomic changes on treatment of lung cancer
-
Cardarella S, Johnson BE,. The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 2013; 188: 770-775.
-
(2013)
Am J Respir Crit Care Med
, vol.188
, pp. 770-775
-
-
Cardarella, S.1
Johnson, B.E.2
-
27
-
-
48249114422
-
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
-
Koivunen JP, Mermel C, Zejnullahu K, et al., EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-4283.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4275-4283
-
-
Koivunen, J.P.1
Mermel, C.2
Zejnullahu, K.3
-
28
-
-
70349336416
-
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
-
Shaw AT, Yeap BY, Mino-Kenudson M, et al., Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4247-4253
-
-
Shaw, A.T.1
Yeap, B.Y.2
Mino-Kenudson, M.3
-
29
-
-
80053386829
-
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis
-
Shaw AT, Yeap BY, Solomon BJ, et al., Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-1012.
-
(2011)
Lancet Oncol
, vol.12
, pp. 1004-1012
-
-
Shaw, A.T.1
Yeap, B.Y.2
Solomon, B.J.3
-
30
-
-
69349083935
-
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
-
Rodig SJ, Mino-Kenudson M, Dacic S, et al., Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15: 5216-5223.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5216-5223
-
-
Rodig, S.J.1
Mino-Kenudson, M.2
Dacic, S.3
-
31
-
-
77953291664
-
The biology and treatment of EML4-ALK non-small cell lung cancer
-
Sasaki T, Rodig SJ, Chirieac LR, et al., The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46: 1773-1780.
-
(2010)
Eur J Cancer
, vol.46
, pp. 1773-1780
-
-
Sasaki, T.1
Rodig, S.J.2
Chirieac, L.R.3
-
32
-
-
84880917013
-
Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant
-
To KF, Tong JH, Yeung KS, et al., Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. J Thorac Oncol 2013; 8: 883-891.
-
(2013)
J Thorac Oncol
, vol.8
, pp. 883-891
-
-
To, K.F.1
Tong, J.H.2
Yeung, K.S.3
-
33
-
-
84863338079
-
ROS1 rearrangements define a unique molecular class of lung cancers
-
Bergethon K, Shaw AT, Ou SH, et al., ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-870.
-
(2012)
J Clin Oncol
, vol.30
, pp. 863-870
-
-
Bergethon, K.1
Shaw, A.T.2
Ou, S.H.3
-
34
-
-
84865089246
-
Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: Identification of a FIG-ROS1 fusion
-
Rimkunas VM, Crosby KE, Li D, et al., Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012; 18: 4449-4457.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 4449-4457
-
-
Rimkunas, V.M.1
Crosby, K.E.2
Li, D.3
-
35
-
-
84880664490
-
Novel targets in non-small cell lung cancer: ROS1 and RET fusions
-
Gainor JF, Shaw AT,. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013; 18: 865-875.
-
(2013)
Oncologist
, vol.18
, pp. 865-875
-
-
Gainor, J.F.1
Shaw, A.T.2
-
36
-
-
84865092224
-
Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement
-
abstract 7508.
-
Shaw AT, Camidge DR, Engelman JA,. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 2012; 30 (Suppl): abstract 7508.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Shaw, A.T.1
Camidge, D.R.2
Engelman, J.A.3
-
37
-
-
84878975043
-
Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib
-
Bos M, Gardizi M, Schildhaus HU, et al., Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer 2013; 81: 142-143.
-
(2013)
Lung Cancer
, vol.81
, pp. 142-143
-
-
Bos, M.1
Gardizi, M.2
Schildhaus, H.U.3
-
38
-
-
84863230117
-
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
-
Ju YS, Lee WC, Shin JY, et al., A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012; 22: 436-445.
-
(2012)
Genome Res
, vol.22
, pp. 436-445
-
-
Ju, Y.S.1
Lee, W.C.2
Shin, J.Y.3
-
39
-
-
84857929267
-
KIF5B-RET fusions in lung adenocarcinoma
-
Kohno T, Ichikawa H, Totoki Y, et al., KIF5B-RET fusions in lung adenocarcinoma. Nature Med 2012; 18: 375-377.
-
(2012)
Nature Med
, vol.18
, pp. 375-377
-
-
Kohno, T.1
Ichikawa, H.2
Totoki, Y.3
-
40
-
-
84857985225
-
RET, ROS1 and ALK fusions in lung cancer
-
Takeuchi K, Soda M, Togashi Y, et al., RET, ROS1 and ALK fusions in lung cancer. Nature Med 2012; 18: 378-381.
-
(2012)
Nature Med
, vol.18
, pp. 378-381
-
-
Takeuchi, K.1
Soda, M.2
Togashi, Y.3
-
41
-
-
84884986372
-
Molecular genetic testing for lung adenocarcinomas: A practical approach to clinically relevant mutations and translocations
-
Dacic S., Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. J Clin Pathol 2013; 66: 870-874.
-
(2013)
J Clin Pathol
, vol.66
, pp. 870-874
-
-
Dacic, S.1
-
42
-
-
84878858856
-
Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas
-
Drilon A, Wang L, Hasanovic A, et al., Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013; 3: 630-635.
-
(2013)
Cancer Discov
, vol.3
, pp. 630-635
-
-
Drilon, A.1
Wang, L.2
Hasanovic, A.3
-
43
-
-
0345601083
-
Met, metastasis, motility and more
-
Birchmeier C, Birchmeier W, Gherardi E, et al., Met, metastasis, motility and more. Nature Rev Mol Cell Biol 2003; 4: 915-925.
-
(2003)
Nature Rev Mol Cell Biol
, vol.4
, pp. 915-925
-
-
Birchmeier, C.1
Birchmeier, W.2
Gherardi, E.3
-
44
-
-
63849163410
-
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients
-
Cappuzzo F, Marchetti A, Skokan M, et al., Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009; 27: 1667-1674.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1667-1674
-
-
Cappuzzo, F.1
Marchetti, A.2
Skokan, M.3
-
45
-
-
77952519096
-
Clinical implications of MET gene copy number in lung cancer
-
Toschi L, Cappuzzo F,. Clinical implications of MET gene copy number in lung cancer. Future Oncol 2010; 6: 239-247.
-
(2010)
Future Oncol
, vol.6
, pp. 239-247
-
-
Toschi, L.1
Cappuzzo, F.2
-
46
-
-
84862777005
-
Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer
-
Dziadziuszko R, Wynes MW, Singh S, et al., Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012; 7: 340-347.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 340-347
-
-
Dziadziuszko, R.1
Wynes, M.W.2
Singh, S.3
-
47
-
-
38049150665
-
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
-
Bean J, Brennan C, Shih JY, et al., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104: 20932-20937.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 20932-20937
-
-
Bean, J.1
Brennan, C.2
Shih, J.Y.3
-
48
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman JA, Zejnullahu K, Mitsudomi T, et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
-
(2007)
Science
, vol.316
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
-
49
-
-
84877848587
-
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition
-
Katayama R, Aoyama A, Yamori T, et al., Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013; 73: 3087-3096.
-
(2013)
Cancer Res
, vol.73
, pp. 3087-3096
-
-
Katayama, R.1
Aoyama, A.2
Yamori, T.3
-
50
-
-
84877097337
-
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET
-
Basilico C, Pennacchietti S, Vigna E, et al., Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013; 19: 2381-2392.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2381-2392
-
-
Basilico, C.1
Pennacchietti, S.2
Vigna, E.3
-
51
-
-
33750683969
-
A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo
-
Martens T, Schmidt NO, Eckerich C, et al., A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12: 6144-6152.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6144-6152
-
-
Martens, T.1
Schmidt, N.O.2
Eckerich, C.3
-
52
-
-
49249100382
-
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival
-
Jin H, Yang R, Zheng Z, et al., MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68: 4360-4368.
-
(2008)
Cancer Res
, vol.68
, pp. 4360-4368
-
-
Jin, H.1
Yang, R.2
Zheng, Z.3
-
53
-
-
84890108571
-
Randomized phase II trial of onartuzumab (MetMAb) in combination with erlotinib in patients with advanced non-small-cell lung cancer
-
Spigel DR, Ervin TJ, Ramlau R, et al., Randomized phase II trial of onartuzumab (MetMAb) in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013; 31: 4105-4114.
-
(2013)
J Clin Oncol
, vol.31
, pp. 4105-4114
-
-
Spigel, D.R.1
Ervin, T.J.2
Ramlau, R.3
-
54
-
-
84867526394
-
Treatment rationale study design for the MetLung trial: A randomized, double-blind phase III study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV Met-positive non-small-cell lung cancer
-
Spigel DR, Edelman MJ, Mok T, et al., Treatment rationale study design for the MetLung trial: a randomized, double-blind phase III study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV Met-positive non-small-cell lung cancer. Clin Lung Cancer 2012; 13: 500-504.
-
(2012)
Clin Lung Cancer
, vol.13
, pp. 500-504
-
-
Spigel, D.R.1
Edelman, M.J.2
Mok, T.3
-
55
-
-
79958112619
-
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer
-
Dutt A, Ramos AH, Hammerman PS, et al., Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6: e20351.
-
(2011)
PLoS One
, vol.6
-
-
Dutt, A.1
Ramos, A.H.2
Hammerman, P.S.3
-
56
-
-
84884527235
-
S49076 is a novel kinase inhibitor of MET, AXL and FGFR with strong preclinical activity alone and in association with bevacizumab
-
Burbridge MF, Bossard CJ, Saunier C, et al., S49076 is a novel kinase inhibitor of MET, AXL and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther 2013; 12: 1749-1762.
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 1749-1762
-
-
Burbridge, M.F.1
Bossard, C.J.2
Saunier, C.3
-
57
-
-
84881667061
-
Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer
-
Tran TN, Selinger CI, Kohonen-Corish MR, et al., Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer 2013; 81: 462-467.
-
(2013)
Lung Cancer
, vol.81
, pp. 462-467
-
-
Tran, T.N.1
Selinger, C.I.2
Kohonen-Corish, M.R.3
-
58
-
-
84860120185
-
AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family
-
Gavine PR, Mooney L, Kilgour E, et al., AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72: 2045-2056.
-
(2012)
Cancer Res
, vol.72
, pp. 2045-2056
-
-
Gavine, P.R.1
Mooney, L.2
Kilgour, E.3
-
59
-
-
84871217393
-
Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models
-
Zhang J, Zhang L, Su X, et al., Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res 2012; 18: 6658-6667.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 6658-6667
-
-
Zhang, J.1
Zhang, L.2
Su, X.3
-
60
-
-
84876240753
-
Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1
-
Ren M, Hong M, Liu G, et al., Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep 2013; 29: 2181-2190.
-
(2013)
Oncol Rep
, vol.29
, pp. 2181-2190
-
-
Ren, M.1
Hong, M.2
Liu, G.3
-
61
-
-
84890297953
-
Phosphatase and tensin homologue deleted on chromosome 10
-
Abdulkareem IH, Blair M,. Phosphatase and tensin homologue deleted on chromosome 10. Niger Med J 2013; 54: 79-86.
-
(2013)
Niger Med J
, vol.54
, pp. 79-86
-
-
Abdulkareem, I.H.1
Blair, M.2
-
62
-
-
84866894408
-
Comprehensive genomic characterization of squamous cell lung cancers
-
The Cancer Genome Atlas Research Network.
-
The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
-
(2012)
Nature
, vol.489
, pp. 519-525
-
-
-
63
-
-
23444461754
-
PTEN expression in non-small cell lung cancer: Evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration
-
Marsit CJ, Zheng S, Aldape K, et al., PTEN expression in non-small cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005; 36: 768-776.
-
(2005)
Hum Pathol
, vol.36
, pp. 768-776
-
-
Marsit, C.J.1
Zheng, S.2
Aldape, K.3
-
64
-
-
84883347910
-
Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap)
-
Dearden S, Stevens J, Wu YL, et al., Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24: 2371-2376.
-
(2013)
Ann Oncol
, vol.24
, pp. 2371-2376
-
-
Dearden, S.1
Stevens, J.2
Wu, Y.L.3
-
65
-
-
84875518717
-
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency
-
Takeda H, Takigawa N, Ohashi K, et al., Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res 2013; 319: 417-423.
-
(2013)
Exp Cell Res
, vol.319
, pp. 417-423
-
-
Takeda, H.1
Takigawa, N.2
Ohashi, K.3
-
66
-
-
11144358645
-
High frequency of mutations of the PIK3CA gene in human cancers
-
Samuels Y, Wang Z, Bardelli A, et al., High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
-
(2004)
Science
, vol.304
, pp. 554
-
-
Samuels, Y.1
Wang, Z.2
Bardelli, A.3
-
67
-
-
84879636044
-
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features
-
Trigka EA, Levidou G, Saetta AA, et al., A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep 2013; 30: 623-636.
-
(2013)
Oncol Rep
, vol.30
, pp. 623-636
-
-
Trigka, E.A.1
Levidou, G.2
Saetta, A.A.3
-
68
-
-
84856823963
-
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma: Rationale for comprehensive mutation profiling
-
Chaft JE, Arcila ME, Paik PK, et al., Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma: rationale for comprehensive mutation profiling. Mol Cancer Ther 2012; 11: 485-491.
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 485-491
-
-
Chaft, J.E.1
Arcila, M.E.2
Paik, P.K.3
-
69
-
-
84880672380
-
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
-
Pfeifer M, Grau M, Lenze D, et al., PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013; 110: 12420-12425.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 12420-12425
-
-
Pfeifer, M.1
Grau, M.2
Lenze, D.3
-
70
-
-
84874575400
-
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
-
Thomas A, Rajan A, Lopez-Chavez A, et al., From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol 2013; 24: 577-585.
-
(2013)
Ann Oncol
, vol.24
, pp. 577-585
-
-
Thomas, A.1
Rajan, A.2
Lopez-Chavez, A.3
-
71
-
-
84879677951
-
A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells
-
Lee H, Kim SJ, Jung KH, et al., A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells. Oncol Rep 2013; 30: 863-869.
-
(2013)
Oncol Rep
, vol.30
, pp. 863-869
-
-
Lee, H.1
Kim, S.J.2
Jung, K.H.3
-
72
-
-
84871574719
-
Beyond the standard of care: A review of novel immunotherapy trials for the treatment of lung cancer
-
Hall RD, Gray JE, Chiappori AA,. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 2013; 20: 22-31.
-
(2013)
Cancer Control
, vol.20
, pp. 22-31
-
-
Hall, R.D.1
Gray, J.E.2
Chiappori, A.A.3
-
73
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQM, et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.M.3
-
74
-
-
84871192340
-
Molecular pathways: Next-generation immunotherapy - Inhibiting programmed death-ligand 1 and programmed death-1
-
Chen DS, Irving BA, Hodi FS,. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012; 18: 6580-6587.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 6580-6587
-
-
Chen, D.S.1
Irving, B.A.2
Hodi, F.S.3
-
75
-
-
84880706152
-
Oncology meets immunology: The cancer-immunity cycle
-
Chen DS, Mellman I,. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1-10.
-
(2013)
Immunity
, vol.39
, pp. 1-10
-
-
Chen, D.S.1
Mellman, I.2
-
76
-
-
84879465848
-
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)
-
Velcheti V, Rimm DL, Schalper KA,. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol 2013; 8: 803-805.
-
(2013)
J Thorac Oncol
, vol.8
, pp. 803-805
-
-
Velcheti, V.1
Rimm, D.L.2
Schalper, K.A.3
-
77
-
-
84873666114
-
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study
-
Chen YB, Mu CY, Huang JA, et al., Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 2012; 98: 751-755.
-
(2012)
Tumori
, vol.98
, pp. 751-755
-
-
Chen, Y.B.1
Mu, C.Y.2
Huang, J.A.3
-
78
-
-
84880715077
-
Survival and long-term follow-up of the phase i trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with previously treated advanced non-small cell lung cancer (NSCLC)
-
abstract 8030.
-
Brahmer JR, Horn L, Antonia SJ, et al., Survival and long-term follow-up of the phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with previously treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2013; 31 (Suppl): abstract 8030.
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
Brahmer, J.R.1
Horn, L.2
Antonia, S.J.3
-
79
-
-
84876413146
-
Clinical activity and safety of anti-programmed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients with advanced non-small cell lung cancer (NSCLC)
-
abstract 1237PD.
-
Gettinger S, Horn L, Antonio SJ, et al., Clinical activity and safety of anti-programmed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2012; 23 (Suppl 9): abstract 1237PD.
-
(2012)
Ann Oncol
, vol.23
, Issue.SUPPL. 9
-
-
Gettinger, S.1
Horn, L.2
Antonio, S.J.3
-
80
-
-
84880709088
-
Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
-
abstract 8008 and updated data presented at the meeting.
-
Spigel DR, Gettinger SN, Hom L, et al., Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2013; 31 (Suppl): abstract 8008 and updated data presented at the meeting.
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
Spigel, D.R.1
Gettinger, S.N.2
Hom, L.3
-
81
-
-
65549149073
-
The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer
-
Gryshkova V, Goncharuk I, Gurtovyy V, et al., The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer. Exp Oncol 2009; 31: 37-42.
-
(2009)
Exp Oncol
, vol.31
, pp. 37-42
-
-
Gryshkova, V.1
Goncharuk, I.2
Gurtovyy, V.3
-
82
-
-
80053391211
-
Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues
-
Kiyamova R, Shyian M, Lyzogubov VV, et al., Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues. Exp Oncol 2011; 33: 157-161.
-
(2011)
Exp Oncol
, vol.33
, pp. 157-161
-
-
Kiyamova, R.1
Shyian, M.2
Lyzogubov, V.V.3
-
83
-
-
84890307872
-
A phase i study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC)
-
abstract 2507.
-
Gordon MS, Gerber DE, Infante JR, et al., A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC). J Clin Oncol 2013; 31 (Suppl): abstract 2507.
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
Gordon, M.S.1
Gerber, D.E.2
Infante, J.R.3
-
84
-
-
84855806726
-
-
National Comprehensive Cancer Network Version 3 [Accessed 22 August 2013]
-
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology; Non-Small Cell Lung Cancer. Version 3; 2012 [Accessed 22 August 2013]. Available from: http://www.nccn.com.
-
(2012)
Clinical Practice Guidelines in Oncology; Non-Small Cell Lung Cancer
-
-
-
85
-
-
79957492069
-
American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
-
Keedy VL, Temin S, Somerfield MR, et al., American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29: 2121-2127.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2121-2127
-
-
Keedy, V.L.1
Temin, S.2
Somerfield, M.R.3
-
86
-
-
84858190933
-
Biomarker discovery, development, and implementation in France: A report from the French National Cancer Institute and cooperative groups
-
Andre F, Nowak F, Arnedos M, et al., Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. Clin Cancer Res 2012; 18: 1555-1560.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1555-1560
-
-
Andre, F.1
Nowak, F.2
Arnedos, M.3
-
87
-
-
84890295430
-
-
Lung Cancer Mutation Consortium (LCMC). [Accessed 22 August 2013]
-
Lung Cancer Mutation Consortium (LCMC). [Accessed 22 August 2013]. Available from: http://www.golcmc.com/index.html.
-
-
-
-
88
-
-
80555139776
-
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC)
-
abstract CRA7506.
-
Kris MG, Johnson BE, Kwiatkowski DJ, et al., Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011; 29 (Suppl): abstract CRA7506.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Kris, M.G.1
Johnson, B.E.2
Kwiatkowski, D.J.3
-
90
-
-
84884538692
-
A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC)
-
abstract 8019.
-
Johnson BE, Kris MG, Berry LD, et al., A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: the Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2013; 31 (Suppl): abstract 8019.
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
Johnson, B.E.1
Kris, M.G.2
Berry, L.D.3
-
91
-
-
78649680251
-
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer
-
Zhu CQ, Ding K, Strumpf D, et al., Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010; 28: 4417-4424.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4417-4424
-
-
Zhu, C.Q.1
Ding, K.2
Strumpf, D.3
-
92
-
-
84861985508
-
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: Development and international validation studies
-
Kratz JR, He J, Van Den Eeden SK, et al., A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012; 379: 823-832.
-
(2012)
Lancet
, vol.379
, pp. 823-832
-
-
Kratz, J.R.1
He, J.2
Van Den Eeden, S.K.3
-
93
-
-
84875152217
-
A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients
-
Tang H, Xiao G, Behrens C, et al., A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res 2013; 19: 1577-1586.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 1577-1586
-
-
Tang, H.1
Xiao, G.2
Behrens, C.3
-
94
-
-
79551511484
-
Genomic medicine in non-small cell lung cancer: Paving the path to personalized care
-
Sriram KB, Larsen JE, Yang IA, et al., Genomic medicine in non-small cell lung cancer: paving the path to personalized care. Respirology 2011; 16: 257-263.
-
(2011)
Respirology
, vol.16
, pp. 257-263
-
-
Sriram, K.B.1
Larsen, J.E.2
Yang, I.A.3
-
95
-
-
27644598230
-
Four-color multiplex reverse transcription polymerase chain reaction - Overcoming its limitations
-
Persson K, Hamby K, Ugozzoli LA,. Four-color multiplex reverse transcription polymerase chain reaction-overcoming its limitations. Anal Biochem 2005; 344: 33-42.
-
(2005)
Anal Biochem
, vol.344
, pp. 33-42
-
-
Persson, K.1
Hamby, K.2
Ugozzoli, L.A.3
-
96
-
-
82355191818
-
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
-
Sequist LV, Heist RS, Shaw AT, et al., Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22: 2616-2624.
-
(2011)
Ann Oncol
, vol.22
, pp. 2616-2624
-
-
Sequist, L.V.1
Heist, R.S.2
Shaw, A.T.3
-
97
-
-
78651079558
-
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer
-
Su Z, Dias-Santagata D, Duke M, et al., A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 2011; 13: 74-84.
-
(2011)
J Mol Diagn
, vol.13
, pp. 74-84
-
-
Su, Z.1
Dias-Santagata, D.2
Duke, M.3
-
98
-
-
84871325703
-
Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel
-
Patel R, Tsan A, Tam R, et al., Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel. PLoS One 2012; 7: e51153.
-
(2012)
PLoS One
, vol.7
-
-
Patel, R.1
Tsan, A.2
Tam, R.3
-
99
-
-
84861976984
-
Whole genome sequencing for lung cancer
-
Daniels M, Goh F, Wright GM, et al., Whole genome sequencing for lung cancer. J Thorac Dis 2012; 4: 155-163.
-
(2012)
J Thorac Dis
, vol.4
, pp. 155-163
-
-
Daniels, M.1
Goh, F.2
Wright, G.M.3
-
100
-
-
65349165823
-
EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer
-
Smouse JH, Cibas ES, Janne PA, et al., EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009; 117: 67-72.
-
(2009)
Cancer
, vol.117
, pp. 67-72
-
-
Smouse, J.H.1
Cibas, E.S.2
Janne, P.A.3
-
101
-
-
84863393080
-
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
-
Gerlinger M, Rowan AJ, Horswell S, et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
-
(2012)
N Engl J Med
, vol.366
, pp. 883-892
-
-
Gerlinger, M.1
Rowan, A.J.2
Horswell, S.3
-
102
-
-
79952419254
-
Methodological and practical challenges for personalized cancer therapies
-
Wistuba II, Gelovani JG, Jacoby JJ, et al., Methodological and practical challenges for personalized cancer therapies. Nature Rev Clin Oncol 2011; 8: 135-141.
-
(2011)
Nature Rev Clin Oncol
, vol.8
, pp. 135-141
-
-
Wistuba, I.I.1
Gelovani, J.G.2
Jacoby, J.J.3
-
103
-
-
84868331240
-
Translating genomic information into clinical medicine: Lung cancer as a paradigm
-
Levy MA, Lovly CM, Pao W,. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res 2012; 22: 2101-2108.
-
(2012)
Genome Res
, vol.22
, pp. 2101-2108
-
-
Levy, M.A.1
Lovly, C.M.2
Pao, W.3
-
104
-
-
84875925170
-
New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials
-
Travis WD, Brambilla E, Riely GJ,. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013; 31: 992-1001.
-
(2013)
J Clin Oncol
, vol.31
, pp. 992-1001
-
-
Travis, W.D.1
Brambilla, E.2
Riely, G.J.3
-
105
-
-
29344465338
-
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients
-
Yauch RL, Januario T, Eberhard DA, et al., Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005; 11 (24 Pt 1): 8686-8698.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.24
, pp. 8686-8698
-
-
Yauch, R.L.1
Januario, T.2
Eberhard, D.A.3
-
106
-
-
79957857433
-
The BATTLE trial: Personalizing therapy for lung cancer
-
Kim ES, Herbst RS, Wistuba II, et al., The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44-53.
-
(2011)
Cancer Discov
, vol.1
, pp. 44-53
-
-
Kim, E.S.1
Herbst, R.S.2
Wistuba, I.I.3
|